Early recapture of response with tofacitinib 10 mg twice daily in patients with ulcerative colitis in OCTAVE Open following dose reduction or treatment interruption in OCTAVE Sustain.
Jessica R AllegrettiKrisztina B GecseMichael V ChioreanMarjorie ArgolloXiang GuoNervin LawendyChinyu SuRajiv MundayatJerome PaulissenLeonardo SalesePeter M IrvingPublished in: Journal of gastroenterology and hepatology (2023)
Rectal bleeding improvement and stool frequency improvement were achieved by M1 in many patients receiving tofacitinib 10 mg BID in both subpopulations, with no apparent difference by prior TNFi failure. Analyses were limited by small sample sizes for some subgroups.